Holen Sie sich die Stockscreener-App
2.12
1.85%
-0.04
Handel nachbörslich:
2.14
0.02
+0.94%
Schlusskurs vom Vortag:
$2.16
Offen:
$2.14
24-Stunden-Volumen:
41,553
Relative Volume:
0.06
Marktkapitalisierung:
$177.68M
Einnahmen:
$47.04M
Nettoeinkommen (Verlust:
$-63.98M
KGV:
-2.629
EPS:
-0.8064
Netto-Cashflow:
$-34.39M
1W Leistung:
-5.36%
1M Leistung:
+20.45%
6M Leistung:
-5.99%
1J Leistung:
-19.70%
1-Tages-Spanne:
$2.0401
$2.18
1-Wochen-Bereich:
$2.04
$2.59
52-Wochen-Spanne:
$1.29
$3.5107
Innate Pharma Adr Stock (IPHA) Company Profile
Firmenname
Innate Pharma Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie IPHA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
2.12 | 177.68M | 47.04M | -63.98M | -34.39M | -0.8064 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 123.21B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 31.94B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.00B | 3.32B | -860.46M | -1.04B | -8.32 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-09-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | Eingeleitet | Goldman | Neutral |
Innate Pharma Adr Aktie (IPHA) Neueste Nachrichten
Innate Pharma shares retain Buy rating on long-term strategy - Investing.com
Nebius Group N.V (NASDAQ: NBIS)’s Upward Trend Continues - Stocks Register
Earnings call: Innate Pharma Q3 2024 results highlight oncology pipeline - Investing.com
Earnings call: Innate Pharma focuses on advancing cancer therapies - Investing.com
Earnings call: Innate Pharma focuses on advancing cancer therapies By Investing.com - Investing.com UK
Earnings call: Innate Pharma reports progress in drug development - Investing.com India
Earnings call: Innate Pharma reports progress in oncology pipeline - Investing.com
Contrast Security Introduces Application Detection and Response (ADR) to Identify and Block Attacks and Zero Days on Applications in Production - Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 - Business Wire
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities News
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
IPHA stock surges on upcoming presentation for AstraZeneca-partnered asset - Seeking Alpha
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
Finanzdaten der Innate Pharma Adr-Aktie (IPHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.22%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):